

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5821465

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
INTERNATIONAL BUSINESS MACHINES CORPORATION	11/06/2019

**RECEIVING PARTY DATA**

<b>Name:</b>	DAEDALUS GROUP LLC
<b>Street Address:</b>	51 PONDFIELD ROAD
<b>Internal Address:</b>	SUITE 3
<b>City:</b>	BRONXVILLE
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10708

**PROPERTY NUMBERS Total: 86**

Property Type	Number
Patent Number:	7249170
Patent Number:	8041786
Patent Number:	8219662
Patent Number:	8769342
Patent Number:	7054946
Patent Number:	7313625
Patent Number:	7007063
Patent Number:	6914969
Patent Number:	6690782
Patent Number:	6690783
Patent Number:	6694002
Patent Number:	9626684
Patent Number:	9031858
Patent Number:	9685048
Patent Number:	9092808
Patent Number:	9361623
Patent Number:	8831972
Patent Number:	8775238
Patent Number:	9031857

PATENT

<b>Property Type</b>	<b>Number</b>
Patent Number:	9846883
Patent Number:	8224496
Patent Number:	8594855
Patent Number:	7120650
Patent Number:	7072894
Patent Number:	7024582
Patent Number:	6990478
Patent Number:	7616971
Patent Number:	7506030
Patent Number:	7373310
Patent Number:	7945464
Patent Number:	7747661
Patent Number:	8195724
Patent Number:	7139791
Patent Number:	8005965
Patent Number:	7383515
Patent Number:	7800701
Patent Number:	7631131
Patent Number:	8769269
Patent Number:	8756013
Patent Number:	8768625
Patent Number:	7159216
Patent Number:	7877485
Patent Number:	8489605
Patent Number:	8768928
Patent Number:	7813255
Patent Number:	8768915
Patent Number:	6898617
Patent Number:	9053192
Patent Number:	7774450
Patent Number:	7409676
Patent Number:	8006230
Patent Number:	7747426
Patent Number:	8769126
Patent Number:	7660247
Patent Number:	7523219
Patent Number:	7003083
Patent Number:	7424098

Property Type	Number
Patent Number:	7512219
Patent Number:	7965824
Patent Number:	7469416
Patent Number:	8312082
Patent Number:	8745712
Patent Number:	7424537
Patent Number:	8768742
Application Number:	11044569
Application Number:	12157250
Application Number:	11862323
Application Number:	11861520
Application Number:	11861590
Application Number:	11744024
Application Number:	11764524
Application Number:	11861528
Application Number:	11862374
Application Number:	60214127
Application Number:	09750320
Application Number:	09885634
Application Number:	60325290
Application Number:	60952622
Application Number:	13903488
Application Number:	11868485
Application Number:	11753956
PCT Number:	US2002030936
PCT Number:	US2002035750
PCT Number:	US2004023126
PCT Number:	US2001045669
PCT Number:	US2001045670

**CORRESPONDENCE DATA**

**Fax Number:** (303)863-0223

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** (303)863-9700

**Email:** spansini@sheridanross.com

**Correspondent Name:** SHERIDAN ROSS PC

**Address Line 1:** 1560 BROADWAY, SUITE 1200

**Address Line 4:** DENVER, COLORADO 80202

<b>ATTORNEY DOCKET NUMBER:</b>	10297
<b>NAME OF SUBMITTER:</b>	MATTHEW R. ELLSWORTH
<b>SIGNATURE:</b>	/Matthew R. Ellsworth/
<b>DATE SIGNED:</b>	11/14/2019

**Total Attachments: 11**

source=IBM Daedalus Second Amendment 11-06-19 Execution (Daedalus & IBM Executed)#page1.tif  
source=IBM Daedalus Second Amendment 11-06-19 Execution (Daedalus & IBM Executed)#page2.tif  
source=IBM Daedalus Second Amendment 11-06-19 Execution (Daedalus & IBM Executed)#page3.tif  
source=IBM Daedalus Second Amendment 11-06-19 Execution (Daedalus & IBM Executed)#page4.tif  
source=IBM Daedalus Second Amendment 11-06-19 Execution (Daedalus & IBM Executed)#page5.tif  
source=IBM Daedalus Second Amendment 11-06-19 Execution (Daedalus & IBM Executed)#page6.tif  
source=IBM Daedalus Second Amendment 11-06-19 Execution (Daedalus & IBM Executed)#page7.tif  
source=IBM Daedalus Second Amendment 11-06-19 Execution (Daedalus & IBM Executed)#page8.tif  
source=IBM Daedalus Second Amendment 11-06-19 Execution (Daedalus & IBM Executed)#page9.tif  
source=IBM Daedalus Second Amendment 11-06-19 Execution (Daedalus & IBM Executed)#page10.tif  
source=IBM Daedalus Second Amendment 11-06-19 Execution (Daedalus & IBM Executed)#page11.tif

**EXECUTION**License Reference Number **L190320**

SECOND AMENDMENT (“Second Amendment”) dated as of the date upon which it has been signed by the second party to so sign, as indicated below (“Second Amendment Date”), to the Patent Assignment Agreement (hereinafter “Agreement” with an Effective Time and Date as set forth therein”) between INTERNATIONAL BUSINESS MACHINES CORPORATION, a New York corporation (“IBM”), and DAEDALUS GROUP LLC. (“BUYER”), a Delaware corporation, on the other hand.

WHEREAS, BUYER and IBM previously amended the Agreement (L190320) pursuant to a first Amendment dated October 25, 2019 which assigned Additional Patents chosen by BUYER for certain non-transferable patent family members;

WHEREAS, IBM has identified all remaining additional patents and patent applications as set forth in Section A, below (“Remaining Additional Patents”) to be assigned to BUYER as patent family members of the Assigned Patents, and the parties agree to further amend the Agreement (L190320) to include the Remaining Additional Patents chosen by BUYER;

WHEREAS, IBM has the right to assign its interest in the Remaining Additional Patents as defined below;

WHEREAS, subject to the licenses from BUYER and the reservation by IBM of certain rights, IBM desires to assign its ownership interest in the Remaining Additional Patents and BUYER desires to acquire such ownership interest in the Remaining Additional Patents;

WHEREAS, in accordance with the definition of “Reversion Event” as set forth in Section 7. Definitions of the Agreement, IBM determined that four (4) of the Assigned Patents-II from Exhibits A-II and B-II of the Agreement failed IBM’s internal review of such patents and thus are “Reversion Assigned Patents-II”;

WHEREAS, on October 14, 2019 at 5:03 PM EST (“Reversion Effective Date”), IBM provided written notice of the Reversion Event and the Reversion Assigned Patents-II to BUYER in accordance with Sections 4.4 and 6.1 of the Agreement in an e-mail from Lydia M. Do to Ed Gomez;

WHEREAS, on the Reversion Effective Date, the Reversion Assigned Patents-II reverted from BUYER to IBM pursuant to Section 6.1 of the Agreement, and for the avoidance of doubt IBM and BUYER desire to confirm such reversion in this Second Amendment;

WHEREAS, effective on the Reversion Effective Date, BUYER had and has the right to assign its interest in the Reversion Assigned Patents-II as defined below; and

WHEREAS, BUYER represents and warrants to IBM that BUYER granted no license under the Reversion Assigned Patents-II to any third party.

Now therefore, in consideration of the premises and covenants herein contained, IBM and BUYER agree as follows:

A. Amendments to Agreement

1) Add the following Remaining Additional Patents to the end of Exhibit A-I (Granted US Patents):

<b>IBM Docket Number</b>	<b>Country</b>	<b>Patent Number</b>	<b>Application Number</b>	<b>Filing Date</b>	<b>Issue Date</b>
*AUS920105001US1	US	7249170	09/730864	12/6/2000	7/24/2007
*AUS920105001US2	US	8041786	11/762591	6/13/2007	10/18/2011
AUS920105002US1	US	8219662	09/730680	12/6/2000	7/10/2012
AUS920105002US2	US	8769342	13/541808	7/5/2012	7/1/2014
*AUS920105012US1	US	7054946	09/730671	12/6/2000	5/30/2006
*AUS920105012US2	US	7313625	11/273293	11/14/2005	12/25/2007
*BOC920000091US1	US	7007063	09/864696	5/24/2001	2/28/2006
*BOC920000094US1	US	6914969	09/884577	6/18/2001	7/5/2005
*BOC920000095US1	US	6690782	09/884576	6/18/2001	2/10/2004
BOC920000096US1	US	6690783	09/884578	6/18/2001	2/10/2004
BOC920000097US1	US	6694002	09/884497	6/18/2001	2/17/2004
END920070007US1	US	9626684	11/695983	4/3/2007	4/18/2017
END920070007US4	US	9031858	11/861729	9/26/2007	5/12/2015
END920070007US5	US	9685048	11/862279	9/27/2007	6/20/2017
END920070007US6	US	9092808	11/862294	9/27/2007	7/28/2015
END920070007US7	US	9361623	11/862299	9/27/2007	6/7/2016
END920070007US8	US	8831972	11/862306	9/27/2007	9/9/2014
END920070007US9	US	8775238	11/862320	9/27/2007	7/8/2014
END920070153US1	US	9031857	11/743982	5/3/2007	5/12/2015
END920070156US1	US	9846883	11/756198	5/31/2007	12/19/2017
*END920080362US1	US	8224496	12/389554	2/20/2009	7/17/2012
*END920080362US2	US	8594855	13/455755	4/25/2012	11/26/2013
*IL920000042US2	US	7120650	09/887549	6/25/2001	10/10/2006
*IL920000042US3	US	7072894	09/887576	6/25/2001	7/4/2006
*IL920000067US2	US	7024582	09/887533	6/25/2001	4/4/2006
*IL920000067US3	US	6990478	09/887520	6/25/2001	1/24/2006
LOT920000043US4	US	7616971	09/885151	6/20/2001	11/10/2009
LOT920000043US5	US	7506030	11/291829	12/2/2005	3/17/2009
LOT920050030US1	US	7373310	09/828710	4/6/2001	5/13/2008
*LOT920050030US2	US	7945464	11/758778	6/6/2007	5/17/2011

\*inactive

2) Add the following Remaining Additional Patents to the end of Exhibit A-II (Granted US Patents):

<b>IBM Docket Number</b>	<b>Country</b>	<b>Patent Number</b>	<b>Application Number</b>	<b>Filing Date</b>	<b>Issue Date</b>
*ARC920050051US1	US	7747661	11/244269	10/5/2005	6/29/2010
*ARC920050051US2	US	8195724	12/781021	5/17/2010	6/5/2012
*AUS920000257US1	US	7139791	09/616140	7/13/2000	11/21/2006
*AUS920010245US1	US	8005965	09/896195	6/30/2001	8/23/2011
*AUS920020353US1	US	7383515	10/205106	7/25/2002	6/3/2008
*AUS920040945US2	US	7800701	12/135543	6/9/2008	9/21/2010
*AUS920050455US1	US	7631131	11/260579	10/27/2005	12/8/2009
*AUS920100247US1	US	8769269	12/855323	8/12/2010	7/1/2014
*AUS920110357US1	US	8756013	13/443163	4/10/2012	6/17/2014
*AUS920110357US2	US	8768625	13/781634	2/28/2013	7/1/2014
*BEA920010005US1	US	7159216	10/013732	11/7/2001	1/2/2007
*BEA920050045US1	US	7877485	11/292774	12/2/2005	1/25/2011
*CA920100033US1	US	8489605	13/167170	6/23/2011	7/16/2013
*CA920100033US2	US	8768928	13/411725	3/5/2012	7/1/2014
*CH920030030US2	US	7813255	12/126467	5/23/2008	10/12/2010
*CN920090067US1	US	8768915	12/916412	10/29/2010	7/1/2014
*END919990058US1	US	6898617	09/443202	11/18/1999	5/24/2005
*END920130067US3	US	9053192	13/930523	6/28/2013	6/9/2015
*JP920030034US2	US	7774450	12/052297	3/20/2008	8/10/2010
*JP920030099US1	US	7409676	10/689417	10/20/2003	8/5/2008
*JP920030099US3	US	8006230	12/098508	4/7/2008	8/23/2011
*JP920050079US1	US	7747426	11/292775	12/2/2005	6/29/2010
*LOT920040018US1	US	8769126	10/875970	6/24/2004	7/1/2014
*ROC920040009US2	US	7660247	12/018226	1/23/2008	2/9/2010
*RSW920000090US2	US	7523219	12/099499	4/8/2008	4/21/2009
*RSW920000128US1	US	7003083	09/782773	2/13/2001	2/21/2006
*RSW920000128US2	US	7424098	10/632177	7/31/2003	9/9/2008
*RSW920000128US4	US	7512219	11/868487	10/6/2007	3/31/2009
*RSW920000128US5	US	7965824	12/053554	3/22/2008	6/21/2011
*RSW920020093US1	US	7469416	10/288082	11/5/2002	12/23/2008
*RSW920090099US2	US	8312082	13/345195	1/6/2012	11/13/2012
*TW920110014US1	US	8745712	13/598538	8/29/2012	6/3/2014

*YOR920030215US1	US	7424537	10/624107	7/21/2003	9/9/2008
*YOR920100635US1	US	8768742	13/369918	2/9/2012	7/1/2014

\*inactive



3) Add the following Remaining Additional Patents to the end of Exhibit B-1 (Granted non-US Patents):

<b>IBM Docket Number</b>	<b>Country</b>	<b>Patent Number</b>	<b>Application Number</b>	<b>Filing Date</b>	<b>Issue Date</b>
AUS920105001CA1	CA	2434241	2434241	12/5/2001	4/8/2014
AUS920105012CA1	CA	2434249	2434249	12/5/2001	4/29/2014
BOC920000091CN1	CN	ZL02810557.5	02810557.5	5/14/2002	1/27/2010
*AUS920105001DE1	DE	60130808.5	01989846.9	12/5/2001	10/3/2007
*BOC920000091DE1	DE	60221118.2	02730419.5	5/14/2002	7/11/2007
AUS920105001EP1	EP	1384349	01989846.9	12/5/2001	10/3/2007
*BOC920000091EP1	EP	1389395	02730419.5	5/14/2002	7/11/2007
*BOC920000091FR1	FR	1389395	02730419.5	5/14/2002	7/11/2007
*AUS920105001GB1	GB	1384349	01989846.9	12/5/2001	10/3/2007
*BOC920000091GB1	GB	1389395	02730419.5	5/14/2002	7/11/2007
BOC920000091JP1	JP	3924279	2003-501167	5/14/2002	3/2/2007
*BOC920000091KR1	KR	0602318	2003-7013843	5/14/2002	7/10/2006
*BOC920000096TW1	TW	I226771	91110970	5/23/2002	1/11/2005

\*inactive

4) Add the following Remaining Additional Patents to the end of Exhibit B-II (Granted non-US Patents):

<b>IBM Docket Number</b>	<b>Country</b>	<b>Patent Number</b>	<b>Application Number</b>	<b>Filing Date</b>	<b>Issue Date</b>
*BEA920010005CN1	CN	ZL02821952.X	02821952.X	11/6/2002	8/19/2009
*END919990058CN1	CN	ZL00130939.0	00130939.0	11/14/2000	4/23/2008
*AUS920000257JP1	JP	3887186	2001-207959	7/9/2001	12/1/2006
*AUS920070745JP1	JP	5159530	2008-234633	9/12/2008	12/21/2012
*AUS920145111JP1	JP	4237055	2003-531345	9/30/2002	12/26/2008
*BEA920010005JP1	JP	3965157	2003-542472	11/6/2002	6/1/2007
*END920060312JP1	JP	5090193	2008-017321	1/29/2008	9/21/2012
*END920080006JP1	JP	5159677	2009-064765	3/17/2009	12/21/2012
*JP920030034JP1	JP	3969654	2003-061842	3/7/2003	6/15/2007
*JP920060109JP1	JP	4308241	2006-305614	11/10/2006	5/15/2009
*RAL920000118JP1	JP	3935880	2003-555385	12/9/2002	3/30/2007
*BEA920010005KR1	KR	0754300	2004-7005100	11/6/2002	8/27/2007
*RAL920000118KR1	KR	0603699	2004-7001554	12/9/2002	7/13/2006
*AUS920000257TW1	TW	I232409	90116178	7/2/2001	5/11/2005
*YOR920030215TW1	TW	I299454	93119483	6/30/2004	8/1/2008
*YOR920060331TW1	TW	I471727	97125063	7/3/2008	2/1/2015

\*inactive

5) Add the following Remaining Additional Patents to the end of Exhibit C-I (US Assigned Patent Applications):

<b>IBM Docket Number</b>	<b>Country</b>	<b>Application Number</b>	<b>Filing Date</b>	<b>Published Application Number</b>
*AUS920040656US1	US	11/044569	1/27/2005	20060179077
*AUS920040656US2	US	12/157250	6/9/2008	20080250343
*END920070007US10	US	11/862323	9/27/2007	20090089107
*END920070007US2	US	11/861520	9/26/2007	20080249864
*END920070007US3	US	11/861590	9/26/2007	20080249866
*END920070154US1	US	11/744024	5/3/2007	20080249835
*END920070158US1	US	11/764524	6/18/2007	20080249858
*END920070212US1	US	11/861528	9/26/2007	20080249865
*END920070213US1	US	11/862374	9/27/2007	20080249870
*IL920000042US1	US	60/214127	6/26/2000	
*IL920000067US1	US	60/214127	6/26/2000	
LOT920000043US1	US	09/750320	12/29/2000	20050159136
*LOT920000043US2	US	09/885634	6/20/2001	2002-0087628

\*inactive

(Non-US Assigned Patent Applications):

<b>IBM Docket Number</b>	<b>Country</b>	<b>Application Number</b>	<b>Filing Date</b>	<b>Published Application Number</b>
*IL920000067CA1	CA	2413434	6/19/2001	CA2434241C
*AUS920105012EP1	EP	01984954.6	12/5/2001	1344348
*IL920000067IL1	IL	153454	6/19/2001	IL153454D0
*AUS920105001PCT1	PCT	US2001/45669	12/5/2001	WO/2002/047332
*AUS920105012PCT1	PCT	PCT/US2001/045670	12/5/2001	WO/2002/047326
*BOC920000091PCT1	PCT	GB02/02250	5/14/2002	WO02/098097
*IL920000067PCT1	PCT	IL01/00560	6/19/2001	WO/2002/001410
*END920080362TW1	TW	99104415	2/11/2010	TW201044739A

6) Add the following Remaining Additional Patents to the end of Exhibit C-II (US Assigned Patent Applications):

<b>IBM Docket Number</b>	<b>Country</b>	<b>Application Number</b>	<b>Filing Date</b>	<b>Published Application Number</b>
--------------------------	----------------	---------------------------	--------------------	-------------------------------------

*AUS920145111US1	US	60/325290	9/28/2001	
*END920070081US1	US	60/952622	7/30/2007	
*END920130067US1	US	13/903488	5/28/2013	20140358948
*RSW920000128US3	US	11/868485	10/6/2007	20080031427
*YOR920070104US1	US	11/753956	5/25/2007	20080294777

\*inactive

#### Non-US Assigned Patent Applications

IBM Docket Number	Country	Application Number	Filing Date	Published Application Number
*BEA920010005CA1	CA	2463748	11/6/2002	CA2463748A1
*CA920100033CA1	CA	2706743	6/30/2010	CA2706743A1
*BEA920050045CN1	CN	200680043480.3	12/1/2006	CN101313278A
*BEA920050048CN1	CN	200680043736.0	11/30/2006	CN101313282A
*CN920090067CN1	CN	200910209075.X	10/30/2009	CN102053975A
*FIS920040324CN1	CN	200610080241.7	5/12/2006	CN1881954A
*RAL920000118CN1	CN	02824533.4	12/9/2002	CN 1602485A
*RSW920030201CN1	CN	200510055306.8	3/15/2005	CN 1694448A
*SVL920040028CN1	CN	200510119296.X	11/3/2005	CN 1770170A
*TW920110014CN1	CN	201210326471.2	9/5/2012	CN103685164A
*AUS920000257EP1	EP	01305901.9	7/9/2001	1179774
*AUS920065016EP1	EP	02788218.2	12/20/2002	1461742
*AUS920145111EP1	EP	02763778.4	9/30/2002	EP1451702A1
*BEA920050045EP1	EP	06830284.3	12/1/2006	1960874
*BEA920050048EP1	EP	06819868.8	11/30/2006	1958065
*CH920070023EP1	EP	08100284.2	1/9/2008	N/A
*DE920060072EP1	EP	07103097.7	2/27/2007	N/A
*DE920100074EP1	EP	10192937.0	11/29/2010	N/A
*GB920070066EP1	EP	07110359.2	6/15/2007	N/A
*GB920110069EP1	EP	11183186.3	9/28/2011	N/A
*GB920110104EP1	EP	11176580.6	8/4/2011	N/A
*GB920060084GB1	GB	0620238.6	10/12/2006	GB0620238D0
*GB920120053GB1	GB	1213545.5	7/31/2012	GB201213545D0
*AUS920145111JP2	JP	2008-156746	6/16/2008	2009-003929
*AUS920050455PCT1	PCT	EP2006/067660	10/23/2006	WO2007/048769
*AUS920065016PCT1	PCT	GB2002/005849	12/20/2002	WO/2003/060783
*AUS920070287PCT1	PCT	EP2008/057537	6/16/2008	WO2008/155309
*AUS920145111PCT1	PCT	US02/030936	9/30/2002	WO/2003/027878
*BEA920010005PCT1	PCT	US02/35750	11/6/2002	WO03/040912A1
*BEA920050045PCT1	PCT	EP2006/069217	12/1/2006	WO2007/063132
*BEA920050048PCT1	PCT	EP2006/069141	11/30/2006	WO2007/063103

*CA920100033PCT1	PCT	EP2011/059762	6/13/2011	WO2012/000778
*CAM920080099PCT1	PCT	EP2010/052603	3/2/2010	WO2010/115665
*GB920110069PCT1	PCT	EP2012/061655	6/19/2012	WO2013/045123
*GB920110104PCT1	PCT	IB2012/053897	7/31/2012	WO2013/018025
*IN920090102PCT1	PCT	EP2011/050388	1/13/2011	WO2011/092059
*RAL920000118PCT1	PCT	GB02/05562	12/9/2002	WO03/054739
*RSW920090041PCT1	PCT	EP2010/058044	6/9/2010	WO2010/145972
*TUC920050060PCT1	PCT	EP2006/068389	11/13/2006	WO2007/060103
*YOR920030215PCT1	PCT	US2004/023126	7/19/2004	WO2005/011247
*YOR920070104PCT1	PCT	EP2008/056174	5/20/2008	WO2008/145565
*BEA920010005PH1	PH	1-2004-500638	11/6/2002	WO03/40912
*AUS920070287TW1	TW	97122726	6/18/2008	TW200915097A
*BEA920050045TW1	TW	95144800	12/1/2006	TW200802100A
*CA920100033TW1	TW	100122941	6/29/2011	TW201224807A
*IN920090102TW1	TW	100102516	1/24/2011	TW201205319A
*TW920110014TW1	TW	100131432	8/31/2011	TW201310959A

\*inactive

B. Within thirty (30) days following the Second Amendment Date, IBM shall deliver to BUYER an executed document substantially similar to Exhibit D to the Agreement along with a listing of the Remaining Additional Patents added to the Agreement under this Second Amendment.

C. In all respects and subject to the following sentence, the Remaining Additional Patents shall be treated as Assigned Patents under the Agreement, including, without limitation, with respect to IBM's reserved rights in Section 2 and BUYER'S licenses to IBM in Section 3, and the representations and warranties in Section 5.3 and 5.4. References to the term "Effective Time & Date" shall be deemed to be substituted with the term "Second Amendment Date", but only with respect to the Remaining Additional Patents.

D. For the avoidance of doubt, BUYER and IBM hereby confirm and agree that effective on October 14, 2019 at 5:03 PM EST ("Reversion Effective Date") BUYER transferred and assigned to IBM, and effective on the Reversion Effective Date BUYER hereby transfers and assigns to IBM, all right, title and interest in and to the Reversion Assigned Patents-II listed on the Reversion Assigned Patents-II list attached to this Second Amendment that BUYER has, including the right to sue for injunctive relief and damages for infringement of any of the Reversion Assigned Patents-II accruing on and after the Reversion Effective Date. At BUYER's expense, and without any additional consideration from IBM, BUYER shall execute and deliver to IBM any additional documents and instruments reasonably requested by IBM that are necessary to perfect IBM's right, title and interest in and to such Reversion Assigned Patents-II and recordation thereof.

E. Except as amended by this Second Amendment, all the rights, obligations and liabilities of the parties under the Agreement shall otherwise remain in full force and effect as set out therein.

F. This Amendment may be signed in one or more counterparts, each of which, when signed and delivered, shall be deemed to be an original. All such counterparts together shall constitute one and the same valid and binding agreement, even if all of the parties have not signed the same counterpart. Signatures to this Amendment may be delivered by facsimile, in which case the facsimile copy of an original signature shall be deemed to be an original signature.

The Agreement, as amended by the first Amendment and this Second Amendment, and its and their Exhibits and attachments embody the entire understanding of the parties with respect to the Assigned Patents and the Additional Patents and the Remaining Additional Patents and merges all prior discussions between the parties. Neither party shall be bound by any condition, definition, warranty, understanding, or representation with respect to the subject matter hereof other than as expressly provided herein.

Agreed to:  
DAEDALUS GROUP LLC

By: Ed Gomez

Name: Ed Gomez

Title: Managing Principal

Date: November 5, 2019

Agreed to:  
INTERNATIONAL BUSINESS  
MACHINES CORPORATION

By: Lisa M Regan

Name: Lisa M Regan

Title: VP Finance + Operations,  
Research + Intellectual Property

Date: Nov. 6, 2019

**REVERSION ASSIGNED PATENTS-II**

<b>IBM Docket Number</b>	<b>Country</b>	<b>Patent Number</b>	<b>Application Number</b>	<b>Filing Date</b>	<b>Issue Date</b>
<b>SVL920050581US1</b>	<b>US</b>	<b>8041760</b>	<b>11/065187</b>	<b>2/24/2005</b>	<b>10/18/2011</b>
<b>POU920070067US1</b>	<b>US</b>	<b>8095750</b>	<b>11/928594</b>	<b>10/30/2007</b>	<b>1/10/2012</b>
<b>GB920010033US3</b>	<b>US</b>	<b>8191079</b>	<b>12/052258</b>	<b>3/20/2008</b>	<b>5/29/2012</b>
<b>YOR920100477US1</b>	<b>US</b>	<b>9280335</b>	<b>12/895461</b>	<b>9/30/2010</b>	<b>3/8/2016</b>